TMBleR: a bioinformatic tool to optimize TMB estimation and predictive power.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 34927668.
- Also identified by DOI 10.1093/bioinformatics/btab836.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tumor mutational burden (TMB) has been proposed as a predictive biomarker for immunotherapy response in cancer patients, as it is thought to enrich for tumors with high neoantigen load. TMB assessed by whole-exome sequencing is considered the gold standard but remains confined to research settings. In the clinical setting, targeted gene panels sampling various genomic sizes along with diverse strategies to estimate TMB were proposed and no real standard has emerged yet. We provide the community with TMBleR, a tool to measure the clinical impact of various strategies of panel-based TMB measurement. R package and docker container (GPL-3 Open Source license): https://acc-bioinfo.github.io/TMBleR/. Graphical-user interface website: https://bioserver.ieo.it/shiny/app/tmbler. Supplementary data are available at Bioinformatics online.
Medical subject headings
- Neoplasms